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The translocator protein (TSPO) is upregulated during glia activation in chronic pain patients. TSPO con-
stitutes the rate-limiting step in neurosteroid synthesis, thus modulating synaptic transmission. Related
serotonergic mechanisms influence if pro- or anti-nociceptive neurosteroids are produced. This study
investigated the effects of a functional genetic polymorphism regulating the binding affinity to the
TSPO, thus affecting symptom severity and cerebral pain processing in fibromyalgia patients. Gene-to-
gene interactions with a functional polymorphism of the serotonin transporter gene were assessed.
Fibromyalgia patients (n = 126) were genotyped regarding the polymorphisms of the TSPO (rs6971)
and the serotonin transporter (5-HTTLPR/rs25531). Functional magnetic resonance imaging (n = 24) was
used to study brain activation during individually calibrated pressure pain. Compared to mixed/low
TSPO affinity binders, the high TSPO affinity binders rated more severe pain (p = 0.016) and fibromyalgia
symptoms (p = 0.02). A significant interaction was found between the TSPO and the serotonin transporter
polymorphisms regarding pain severity (p < 0.0001). Functional connectivity analyses revealed that the
TSPO high affinity binding group had more pronounced pain-evoked functional connectivity in the right
frontoparietal network, between the dorsolateral prefrontal area and the parietal cortex. In conclusion,
fibromyalgia patients with the TSPO high affinity binding genotype reported a higher pain intensity
and more severe fibromyalgia symptoms compared to mixed/low affinity binders, and this was modu-
lated by interaction with the serotonin transporter gene. To our knowledge this is the first evidence of
functional genetic polymorphisms affecting pain severity in FM and our findings are in line with proposed
glia-related mechanisms. Furthermore, the functional magnetic resonance findings indicated an effect of
translocator protein on the affective-motivational components of pain perception.
 2016 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Activated glial cells have been reported in animal models of
chronic pain (Milligan and Watkins, 2009; Watkins and Maier,
2005). In humans, glia activation can be studied in vivo, using posi-
tron emission tomography with ligands for the peripheral benzodi-
azepine receptor, more frequently referred to as the translocator
protein (TSPO). Small amounts of TSPO are expressed by glia in
the healthy human brain (Rupprecht et al., 2010), but the expres-
sion is up-regulated during glia activation (Nothdurfter et al.,
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of TSPO has been reported in patients with various psychiatric
(Bloomfield et al., 2016; Pozzo et al., 2012; Setiawan et al., 2015)
and neurological (Girard et al., 2011; Zürcher et al., 2015) disorders
that are linked to glia activation. Recently, increased thalamic TSPO
binding was reported in chronic low back pain patients compared
to healthy controls, thus linking glia cell activation to chronic pain
in humans (Loggia et al., 2015).
Despite the fact that TSPO is an evolutionary well conserved
protein, it’s exact biological roles are yet to be determined
(Gatliff and Campanella, 2016). TSPO is a mitochondrial membrane
protein, important for the regulation of steroid hormone produc-
tion and was believed to be necesasary for survival. This view
was recently challanged by studies showing that TSPO is not nec-
essary for steroid production (Banati et al., 2014; Morohaku
et al., 2014) and by demonstrating an overtly normal phenotype
of TSPO knockout mice, with the exeption of reduced mitochon-
drial ATP production in microglia (Banati et al., 2014). The authors
speculated that TSPO-mediated changes in ATP production might
exert indirect regulatory effects on the energy-dependent steroid
biogenesis, particularly under stress challenges, thus influencing
the course of inflammatory brain pathology (Banati et al., 2014).
However, whereas knockout studies have yielded inconsistent
results most likely due to differences in methodology, strains and
compensatory mechanisms (Gatliff and Campanella, 2016), the evi-
dence supporting an important role of TSPO in cholesterol metabo-
lism and steroidogenesis is abundant (Gatliff and Campanella,
2016).
Previous studies have shown that by controlling the rate-
limiting step in neurosteroid synthesis, TSPO has a large impact
on neurosteroids (Costa et al., 2012; Pozzo et al., 2012). Neuros-
teroids act as potent modulators of synaptic transmission by exert-
ing facilitatory or inhibitory effects on GABA-A receptors, thus
affecting mood, cognition and pain (Aouad et al., 2009;
Nothdurfter et al., 2012; Pozzo et al., 2012). Depending on their
action on the GABA-A receptor subunits, neurosteroids can have
analgesic (positive modulators) or hyperalgesic (negative modula-
tors) effects (Scarf and Kassiou, 2011; Svensson et al., 2013). Sero-
tonergic tone may influence which types of neurosteroids are
synthesised, with low tone favouring negative modulators (Pinna
et al., 2006; Schüle et al., 2011). Thus, whereas TSPO binding affin-
ity regulates the rate of neurosteroid production, serotonergic tone
influences if positive or negative neurosteroid modulators are
synthesised.
The binding affinity to the human TSPO receptor is genetically
determined by a functional polymorphism in the TSPO gene
(rs6971) (Guo et al., 2013; Mizrahi et al., 2013; Owen et al.,
2012; Venneti et al., 2013). This single-nucleotide polymorphism
(SNP) substitutes the amino acid alanine 147 into threonine
(Ala147Thr) in the C-terminal transmembrane domain containing
the cholesterol recognition amino acid consensus sequence
(Costa et al., 2009a). The SNP has been shown to affect neuros-
teroid production (Costa et al., 2009a) and has been associated
with psychiatric diagnosis such as panic disorder (Nakamura
et al., 2006), adult separation anxiety (Costa et al., 2009b), and
bipolar disease (Colasanti et al., 2013).
The amount of serotonin available in the synaptic cleft is genet-
ically regulated by a common, functional polymorphism, the Long
Promoter Repeat (5-HTTLPR) of the serotonin transporter (5-HTT)
gene (SCL6A4) (Lesch et al., 1994). The human promoter region of
the gene SLC6A4 coding for the 5-HTT harbors a 43 base-pair (bp)
insertion/deletion referred to as the 5-HTT linked polymorphic
region (5-HTTLPR). This polymorphism consists of a long (L) allele
and a short (S) allele, the latter coupled to reduced gene-
expression (Lesch et al., 1994). In addition, the promoter region
of the SLC6A4 gene also harbors the single-nucleotide polymor-phism (SNP) rs25531 which includes an A to G substitution
(Wendland et al., 2006). The rs25531 has been shown to further
alter the degree of 5-HTT gene expression. The minor G-allele is
nearly always in phase with the L-allele of the 5-HTTLPR and has
been shown to reduce transcriptional efficacy to the level of the
S-allele (Caspi et al., 2010). When studied jointly, as in the present
study, the mini-haplotypes constructed from 5-HTTLPR and
rs25531 are usually referred to as ‘tri-allelic’ 5-HTTLPR whereas
analysis of only the L/S alleles are termed the ‘biallelic’ assay. Thus,
the tri-allelic 5-HTTLPR permits the functional division of individu-
als into high- (LA/LA), intermediate- (LA/LG, SA/LA) or low- (SA/SA,
SA/LG) expressors of the 5-HTT (Caspi et al., 2010). This polymor-
phism affects endogenous pain modulation (Lindstedt et al.,
2011) and has been associated with fibromyalgia (FM) (Ablin and
Buskila, 2015; Arnold et al., 2013).
FM is characterized by chronic widespread pain and a general-
ized hypersensitivity to sensory stimuli, often in combination with
fatigue, disturbed sleep and psychological distress. FM patients are
characterized by pain hypersensitivity (Kosek et al., 1996) and an
inability to activate endogenous pain inhibitory mechanisms
(Kosek and Hansson, 1997; Lannersten and Kosek, 2010), which
has been supported by neuroimaging studies showing augmented
and abberrant cerebral pain processing (Gracely et al., 2002; Jensen
et al., 2009, 2010, 2012, 2013). Furthermore, glia activation has
been suggested in FM patients based on findings of elevated cere-
brospinal fluid (CSF) concentrations of interleukin-8 (IL-8), com-
pared to controls and patients with rheumatoid arthritis
(Kadetoff et al., 2012; Kosek et al., 2015). The rodent equivalent
of IL-8 (CXCL1) is co-localized with TSPO in glia cells (Liu et al.,
2016). Furthermore, TSPO agonists regulate the expression of
CXCL1 and it’s receptor, thus affecting glia to neuron signalling
and central sensitisation (Liu et al., 2016). Therefore, the elevated
CSF concentrations of IL-8 in FM patients suggest that TSPO associ-
ated mechanisms may be involved in the pathophysiology of FM.
In the present study the influence of the functional polymor-
phism of the TSPO gene on FM symptoms and cerebral pain pro-
cessing was investigated. We hypothesized that if pain in FM is
associated with glia cell activation and TSPO/IL-8 related mecha-
nisms, then genetically inferred differences in TSPO binding affin-
ity would affect FM symptoms. Furthermore, an interaction
between the TSPO and the 5-HTT functional polymorphisms would
be expected.2. Materials and methods
2.1. Subjects
Subjects were recruited to a multi-center experimental study
(ClinicalTrials.gov identification number: NCT01226784) by news-
paper advertisement, where FM patients were randomized to
physical exercise or relaxation therapy (Larsson et al., 2015). Only
baseline data were used in the current study. Out of 402 patients
screened by telephone, 177 were assesed for eligibility at medical
examination and 126 completed baseline examination and geno-
typing and were used for this analysis (Gothenburg n = 38, Linköp-
ing n = 41, Stockholm n = 47). The average age was 51 years, range
22–64 years. Inclusion criteria for FM patients were: female, age
20–65 years, and meeting the ACR-1990 classification criteria for
FM (Wolfe et al., 1990). The patient characteristics are presented
in Table 1. All patients were caucasian. A subgroup (the exercising
part of Stockholm cohort) also performed functional magnetic res-
onance imaging (fMRI), to assess pain-evoked cerebral activations
(n = 24, age 25–64 years).
Exclusion criteria were: high blood pressure (>160/90 mmHg),
osteoarthritis in hip or knee, other severe somatic or psychiatric
Table 1
Characteristics of the participants.
N = 126 Average Range
Age (years) 51.4 22–64
FM duration (years) 10.7 0.5–35
SF-36 bodily pain 34.0 0–74
FIQ total (%) 60.8 16.7–95.3
HAD-A 7.9 0–21
HAD-D 6.7 0–18
PPTs mean (kPa) 183 39–525
SF-36 BP = short form 36 bodily pain score, FIQ = fibromyalgia impact question-
naire, HAD-A = Hospital anxiety and depression scale, anxiety score, HAD-
D = Hospital anxiety and depression scale, depression score, PPTs = pressure pain
thresholds.
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of alcohol (Audit >6 for women according to the Audit version used
in Sweden), participation in a rehabilitation program within the
past year, regular resistance exercise training or relaxation exercise
training twice a week or more, inability to understand or speak
Swedish, and inability to refrain from analgesics, NSAID or hyp-
notics for 48 h prior to study assessments. All patients had a phys-
ical exam to ensure that inclusion criteria were met, and that no
exclusion criteria were present.
The study was approved by the Regional ethics committee in
Stockholm (2010/1121-31/3). Written and oral information was
given to all participants and written consent was obtained from
all participants. The study followed the guidelines of the Declara-
tion of Helsinki.2.2. Procedures
During the first visit (V1), subjects completed standardized
questionnaires regarding pain severity (short form (SF-36) bodily
pain) (Contopoulos-Ioannidis et al., 2009; Hawker et al., 2011),
FM impact (fibromyalgia impact questionnaire (FIQ)) (Bennett
et al., 2005; Hedin et al., 1995) and depression and anxiety (Hospi-
tal Depression and Anxiety Scale (HADS)) (Bjellanda et al., 2002).
SF-36 consists of eight scaled scores, which are the weighted
sums of the questions in their section, ranging from zero (maximal
severity) to 100 (no severity). SF-36 bodily pain (SF-36 BP) is one
subscale of SF-36 and was chosen since it is a validated instrument
to assess pain severity and its interference with working activities,
including housework, over a longer period of time (4 weeks)
(Hawker et al., 2011). Severity of pain was rated on a scale from
1 to 6, ranging from none to very severe, and degree of interference
was rated on a 1–6 scale, ranging from not at all to extreme inter-
ference. SF-36 BP does not segregate between different dimensions
of the painful experience, e.g. pain intensity and pain unpleasant-
ness. The SF-36 BP subscale is often used in patients with FM,
and the different subscales have been used to differentiate FM
from other painful conditions, but also used as an outcome mea-
sure in randomized controlled trials (Wallace and Clauw, 2005).
The FIQ is a disease-specific questionnaire consisting of 20
items assessing symptoms and disability common to FM. The total
score ranges from 0 to 100, where a higher score indicates a lower
health status (Bennett et al., 2005; Hedin et al., 1995). HADS is one
of few psychometric questionnaries that has specifically been
developed for non-psychiatric patients and it consists of two sub-
scales, anxiety and depression, each ranging from zero (no anxiety/
depression) to 21 (maximal anxiety/depression) (Bjellanda et al.,
2002). Pressure pain thresholds (PPTs) were assessed using a pres-
sure algometer (se below). Saliva was collected for genotyping
using Oragene kits (OG-500). The Stockholm cohort returned for
a second visit (V2), for individual calibration of experimental painto be used in the MRI scanner, followed by an fMRI scan the next
day (V3).
2.3. Genotyping
2.3.1. TSPO (Rs6971)
Genotyping was performed using TaqMan SNP genotyping
assays and ABI 7900 HT instrument (Applied Biosystems (ABI), Fos-
ter City, CA). Polymerase chain reactions (PCR), with a total volume
of 5 ll, were performed in 384-well plates containing 2.5 ll
Universal Master Mix (UMM) and 5 ng dried-down genomic DNA
per well. The PCR amplification protocol includes two holds,
50 C for 2 min and denaturation at 95 C for 10 min, followed by
45 cycles at 92 C for 15 s and 60 C for 1 min.
2.3.2. Tri-allelic 5-HTTLPR
For the biallelic 5-HTTLPR, two fragments, 487 bp (short) and
530 bp (long), were amplified by PCR. Each PCR reaction contained
50 ng DNA, 0.2 mM deoxynucleocide triphosphate (dNTP), 0.4 lM
of primer 17P-3F (50-ggcgttgccgctctgaatgc-30), 0.4 lM primer
17P-3R (50-gagggactgagctggacaaccac-30), 0.05 U/ll Quiagen HotS-
tarPolymerase, 1 M Q-solution and finally 1 buffer. Samples
were amplified on Biorade Tetrade (BIORAD, Hercules, CA, USA)
with an initial denaturation for 10 min at 95 C followed by 33
cycles consisting of denaturation for 30 s at 95 C, annealing for
30 s at 57 C and elongation for 5 min at 72 C and finally followed
by another elongation step for 5 min at 72 C. 8 ll of the PCR reac-
tions were separated for 2 h at 100 V by gel-electrophoresis in TBE-
buffer on a 2.5% Agarose gel containing GelRed and visualized
using ultraviolet light (UV).
In order to determine the rs25531, 10 ll of the PCR product
were then digested with 0.1 ll MSP1 (New England Biolabs, Ips-
wich, MA, USA) and 1 ll buffer per sample for 12 h at 37 C. The
MSP1 restriction enzyme breaks the 50-C/CGG0 sequence which
gives rise to fragments of different length from which the tri-
allelic 5-HTTLPR genotype can be determined. LA results in
342 bp, 127 bp and 62 bp; SA results in 298 bp, 127 bp, and
62 bp; LG results in 173 bp, 166 bp, 127 and 62 bp and finally SG
results in 166 bp, 130 bp,127 bp and 62 bp. The fragments were
run on an 4% Agarose gel (3% normal Agarose and 1% low melting
Agarose) containing GelRed initially for 15 min at 70 V followed
by 2 more hours at 100 V. The gels were then visualized with UV
light. We were unable determine the triallelic 5-HTTLPR genotype
for one subject.
2.4. Psychophysical testing
Pressure pain thresholds (PPTs) were assessed in all subjects in
order to get a semi-objective quantification of pain sensitivity.
PPTs were assessed using a pressure algometer (Somedic Sales
AB, Hörby, Sweden); a pistol-shaped apparatus with a 1 cm2 hard
rubber probe that is held at 90 degree angle against the body
and then pressed with a steady rate of increased pressure (approx-
imately 30 kPa/s) until the patient’s pain threshold is reached, and
the corresponding pressure is recorded (Kosek et al., 1993). PPTs
were assessed bilaterally at four different sites, i.e., m. trapezius;
elbows (lateral epicondyle), m. quadriceps femoris and knees (at
the medial fat pad proximal to the joint line), with one assessment
per anatomical site. The average PPT for all body sites (PPTmean)
was calculated for each subject and used for analysis.
2.5. Individual calibration of evoked pain during fMRI
An individual calibration of pressure pain stimuli to be used
during fMRI was performed in the Stockholm cohort. Pressure
stimuli were applied to the left thumbnail for 2.5 s with 30 s inter-
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tor with a plastic piston that applies pressure via a 1 cm2 hard rub-
ber probe (Jensen et al., 2009). In order to avoid sensitisation, the
calibration was performed the day before scannning. Each subject
was calibrated for subjective pain ratings by receiving one ascend-
ing series of pressure stimuli and one randomized series. During
the ascending series the pressure stimuli were presented in steps
of 50 kPa of increased pressure, starting at 50 kPa. The pain thresh-
old, i.e., pressure giving rise to the first VAS rating >0 mm and stim-
ulation maximum, i.e., the pressure eliciting the first rating
exceeding 60 mm on a 0–100 mm visual analogue scale anchored
by ‘‘no pain” and ‘‘worst imaginable pain” was determined. These
values were then used to compute the magnitude of five different
pressure intensities evenly distributed within the range of each
patient’s threshold and maximum. During the randomized series,
a total of 15 stimuli, three of each intensity, were delivered in a
randomized order, and the pain intensity was rated on VAS follow-
ing each stimulus (Jensen et al., 2009). A polynomial regression
function was used to determine each individual’s calibrated pain
rating of 50 mm on the VAS, derived from the 15 randomized rat-
ings (Jensen et al., 2009). The amount of pressure required to evoke
pain at VAS 50 mm in each individual is referred to as P50 through-
out this article.
2.6. Neuroimaging assessments
Patients were placed in the bore of the magnet and asked to
place their left thumb in the pressure-pain device. During fMRI
scanning, two different pressures were used: P50, and a non-
painful pressure corresponding to 50 kPa. All stimulations were
randomly presented over the scanning time, preventing subjects
from anticipating the onset time and event type. The time interval
between stimuli was randomized with a mean stimulus onset
asynchronicity (SOA) of 15 s (range 10–20 s). The total duration
was approximately 16 min. No pain ratings were performed during
the scan, and subjects were instructed to focus on the thumb pres-
sures and not use any distraction or coping strategies.
Images were collected using a 3 T General Electric scanner. Mul-
tiple T2⁄-weighted single-shot gradient echo EPI sequences were
used to acquire blood oxygen level dependent (BOLD) contrast
images with the following parameters: repetition time: 3000 ms
(35 slices acquired), echo time: 40 ms, flip angle: 90 degrees, field
of view: 24  24 cm, 64  64 matrix, 4 mm slice thickness with
0.4 mm gap and sequential image acquisition order. In the scanner,
cushions and headphones were used to reduce head movement
and dampen scanner noise. The placement of a blank screen in
front of the patient’s field of view minimized visual distraction
during scans. In addition to the functional scans, high-resolution
T1-weighted structural images were acquired in coronal orienta-
tion for anatomical reference purposes and screening for cerebral
anomalies. Parameters were: Spoiled Gradient Recalled 3D
sequence, repetition time: 24 ms, echo time: 6 ms, flip angle 35
degrees with a voxel size of 0.9  1.5  0.9 mm3.
2.7. Statistics
First, the effects of the TSPO polymorphism on FM symptoms
were analysed by a Multivariate analysis of variance with SF-36
bodily pain, FIQ total score, HAD-depression, HAD-anxiety and
PPTmean as dependent variables, TSPO as fixed factor and age as
covariate. The same procedure was used to analyse the effects of
the 5-HTT gene polymorphisms on FM symptoms. For dependent
variables where TSPO had a significant effect, the interaction
between TSPO and 5-HTT polymorphisms was analysed by a uni-
variate analysis of variance with the particular factor as dependent
variable and TSPO and 5-HTT as fixed factors. In order to excludethat antidepressive medication influenced our results, we also per-
formed separate analyses for patients on (n = 53, 42%) and off
antidepressants (n = 73, 58%), respectively. Post hoc analysis was
performed using Students’ independent sample t-test. The statisti-
cal analysis was performed using IBM SPSS Statistics version 22.
The data are presented as mean ± standard deviation (SD) if not
otherwise stated. For all non-fMRI analyses, p < 0.05 was consider-
erd significant.2.8. Functional magnetic resonance imaging
Pre-processing and analyses of imaging data were performed
using the Statistical Parametric Mapping 8 (SPM8) software
(http://www.fil.ion.ucl.ac.uk/spm/) and Matlab (Mathworks). All
functional brain volumes were realigned to the first volume, spa-
tially normalized to a standard Echo Planar Imaging template
and finally smoothed using a 8 mm full-width at half-maximum
isotropic Gaussian kernel. Data analysis was performed using the
general linear model (GLM) and modelling of the two different
conditions (‘painful pressure’ and ‘non-painful pressure’). A file
containing the movement parameters for each individual (6 direc-
tions) were obtained from the realignment step and saved for
inclusion in the model. A design matrix was prepared for each sub-
ject and included regressors for the two conditions. To assess pain-
specific cerebral activity, brain activation during non-painful pres-
sures was individually subtracted from activity during the cali-
brated painful pressures.
In the overall analysis of pain-evoked cerebral activity across
genotype groups, an initial image threshold of p < 0.001, uncor-
rected for multiple comparisons, was used together with a cluster
threshold of p < 0.05 Family-Wise Error (FWE) corrected. In all
other analyses, including the psychophysiological interaction
(PPI)-analysis, we adopted an initial image threshold of p < 0.005
and 20 contiguous voxels uncorrected for multiple comparisons
and a cluster threshold of p < 0.05 FWE-corrected. Anatomical loca-
tions were expressed in Montreal Neurological Institute (MNI)
stereotactic atlas coordinates (x, y, z) (Mazziotta et al., 1995).
A PPI analysis was performed based on ‘‘seeds”; i.e. anatomical
locations from which pain-evoked functional connectivity was to
be calculated. A seed coordinate in the dorsolateral Prefrontal Cor-
tex (dlPFC) was defined by a coordinate from the univariate analy-
sis, and chosen based on evidence for dlPFC pain regulatory
functions, together with a seed in the Periaqueductal Grey (PAG)
as it is a key region for descending pain regulation. For each sub-
ject, voxel-wise PPI effects were estimated, and statistical paramet-
ric maps (SPM’s) were produced for the PPI term. The resulting
contrast images were used in a second level PPI group analysis,
comparing the PPI contrast images between TSPO high affinity bin-
der genotype (TSPO HAB) and the pooled TSPO mixed/low affinity
binders (TSPO MLAB) in a two-sample t-test.3. Results
3.1. Genetics
3.1.1. Effects of the functional polymorphism of TSPO and tri-allelic 5-
HTTLPR on FM symptoms
Sixty FM patients had the TSPO high affinity binder (HAB) geno-
type, and 66 were genetically inferred mixed (n = 52) or low affin-
ity binders (n = 14). The data from mixed and low affinity binders
was pooled and is referred to as mixed/low affinity binders (MLAB).
Higher pain severity ratings (p = 0.016) and higher FIQ scores
(p = 0.02) were seen in the genetically inferred TSPO HAB com-
pared to MLAB (Table 2). No statistically significant group differ-
ences were seen regarding depression or anxiety ratings or
Table 2
Impact of genetically inferred TSPO binding affinity and 5-HTT expression on FM symptoms (means and standard deviations).
TSPO HAB (n = 60) TSPO MLAB (n = 66) Statistics p-value 5-HTT-low (n = 28) 5-HTT-inter (n = 64) 5-HTT-high (n = 33) Statistics p-value
SF-36 BP 30.9 ± 11.6 36.9 ± 14.8 p = 0.016 31.0 ± 11.9 34.2 ± 14.3 35.9 ± 13.8 NS
FIQ total (%) 64.3 ± 15.7 57.6 ± 15.6 P = 0.02 61.1 ± 13.4 59.6 ± 17.3 62.3 ± 15.4 NS
HAD-A 8.1 ± 4.3 7.7 ± 4.6 NS 8.3 ± 4.1 7.8 ± 4.5 7.7 ± 4.8 NS
HAD-D 6.9 ± 3.6 6.5 ± 3.7 NS 6.6 ± 3.2 6.7 ± 4.0 6.6 ± 3.2 NS
PPTs (kPa) 178.0 ± 82.4 187.0 ± 77.2 NS 196 ± 76 177 ± 71 184 ± 99 NS
TSPO = Translocator protein, HAB = high affinity binders. MLAB = mixed/low affinity binders, 5-HTT = serotonin transporter, SF-36 BP = short form 36 bodily pain score (lower
score indicates higher pain severity), FIQ = fibromyalgia impact questionnaire, HAD-A = Hospital anxiety and depression scale, anxiety score, HAD-D = Hospital anxiety and
depression scale, depression score, PPTs = pressure pain thresholds. P-values refer to group differences between TSPO HAB/MLAB and 5-HTT low/intermediate and high
expressing, respectively. There was an inverse correlation between SF-36 BP and FIQ (r = 0.599, p < 0.001).
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found no statistically significant effects of the 5-HTT tri-allellic
polymorphism on SF36 bodily pain, FIQ, HADS or PPTmean (Table 2).
A separate analysis was peformed of FM patients on antidepres-
sants (selective serotonin re-uptake inhibitors n = 22, tricyclic
antidepressants n = 15, serotonin-noradrenalin re-uptake inhibi-
tors n = 11, and combinations of these n = 5) and those not taking
antidepressants. There were 24 (45%) MLAB and 29 (55%) HAB tak-
ing anti-depressant medication, to compare with 42 (58%) MLAB
and 31 HAB (42%) among FM patients who were not on antidepres-
sants. We could reproduce our overall findings in the subgroup
without antidepressants, e.g., TSPO HAB had more severe pain
(SF-36 BP m = 31.7) than TSPO MLAB (SF-36 BP = 38.5)(p = 0.036).
However, this was not seen in the subgroup taking antidepressants
(HAB: SF36-BP m = 30.3, MLAB SF-36BP = 33.5) (p = 0.36).0
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Fig. 1. Bodily pain scores across TSPO and 5-HTT genotypes. Average SF-36 bodily pain (
gene-to-gene interaction between the TSPO and the 5-HTT gene regarding pain severity
severity (higher SF-36 BP) was reported in TSPO HAB compared to MLAB (n = 28, p = 0.0
intermediate (n = 64, p = 0.001) or high (n = 33, p = 0.012) expressing FM patients who w
Table 3
Main effects when pooling TSPO HAB and MLAB during painful stimulation (painful press
Anatomical region Cluster size x
L. insula 1214 -44
R. primary sensory cortex 7742 44
L. cerebellum 3360 -28
R. dlPFC 305 38
R. temporal/secondary sensory cortex 725 -52
L. dlPFC 444 -32
Coordinates (x, y, z) correspond to the anatomical space as defined by the MNI standard b
of p < 0.001, uncorrected for multiple comparisons; cluster corrected for multiple compar
L/R. dlPFC = dorsolateral prefrontal cortex, TSPO = Translocator protein, HAB = high affin3.1.2. Effects of gene-to-gene interactions on FM symptoms
There was a statistically significant interaction between the
TSPO and tri-allelic 5-HTT polymorphism regarding pain severity
(df = 2, F = 8.32, p < 0.0001), and this was true also when patients
on antidepressants (df = 2, F = 4.33, p = 0.019) and patients not tak-
ing antidepressants (df = 2, F = 3.26, p = 0.045) were analysed sep-
arately. The TSPO  tri-allelic 5-HTT interaction did not reach
statistical significance regarding FIQ (df = 2, F = 2.81, p = 0.064),
but was in the same direction. Compared to TSPO MLAB, higher
pain severity was reported by TSPO HAB who had genetically
inferred high (n = 33, p = 0.012), or mixed (n = 64, p = 0.001) 5-
HTT expression. However, the opposite was true for the genetically
inferred 5-HTT low expressing subjects, i.e., lower pain severity
ratings were reported by the TSPO HAB compared to MLAB
(n = 28, p = 0.015) (Fig. 1). Within the TSPO MLAB group, higherHigh 5-HTT exprte 5-HTT expr 
 0.001
p < 0.012
SF-36 BP) (means ± SE) in FM patients (n = 126). There was a statistically significant
(p < 0.0001). In genetically inferred 5-HTT low expressing FM patients, lower pain
15). On the contrary, higher pain severity (lower SF-36 BP) was reported in 5-HTT
ere TSPO HAB compared to MLAB.
ure – non-painful pressure).
y z Peak T-value P-value cluster
10 -6 7.88 p < 0.0001
-36 66 7.20 p < 0.0001
-52 -32 7.05 p < 0.0001
44 28 5.54 p < 0.05
-36 16 5.48 p < 0.001
42 28 5.48 p < 0.01
rain atlas (Mazziotta et al., 1995). Results are reported at an initial threshold setting
isons, FWE p < 0.05. Laterality (Left/Right) for anatomical regions are indicated with
ity binders. MLAB = mixed/low affinity binders.
Fig. 3. TSPO genotype differences in dlPFC functional connectivity. Functional
connectivity between the dlPFC and the rest of the brain was estimated using
psychophysiological interaction analyses (PPI). TSPO HAB patients (n = 11) dis-
played higher pain-evoked connectivity than MLAB patients (n = 13) between the
dlPFC seed-region and another anatomical location in the dlPFC (p < 0.001 FWE,
corrected for multiple comparisons), as well as the right parietal cortex (p < 0.005,
FWE corrected for multiple comparisons).
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5-HTT genotype, compared to mixed (p = 0.003) and high
(p = 0.002) expressing, respectively. Paradoxically, within the TSPO
HAB group, the 5-HTT low expressing genotype was associated
with lower pain severity, compared to the intermediate
(p = 0.015) and high (p = 0.106) expressing 5-HTT genotypes.
3.2. Neuroimaging results
3.2.1. Main effect of painful stimulation on brain activity
The fMRI subgroup can be considered representative of the
whole study cohort as no statistically significant differences were
found between this subgroup and the rest of the cohort regarding
age, SF-36 BP, FIQ, HAD or PPTs. There was no statistically signifi-
cant difference in the calibrated thumb pressure (P50) between
TSPO HAB (286 ± 172 kPa) and MLAB patients (233 ± 110 kPa). In
order to validate the pressure pain neuroimaging paradigm, we
calculated the main effect of the painful pressure minus the non-
painful pressure using a one-sample t-test across all FM patients
(TSPO HAB and MLAB pooled, n = 24). As expected, we found acti-
vation in areas traditionally associated with pain processing, such
as the insula, the primary (S1) and secondary (S2) somatosensory
cortex and the cerebellum (Table 3).
3.2.2. Effects of TSPO HAB and MLAB on brain activity
There were no brain regions where the HAB group had greater
brain activations than MLAB. Conversely, the MLAB group had
greater activity in several brain areas (Table 4), including the dor-
solateral prefrontal cortex (dlPFC) (MNI peak coordinate x = 40,
y = 44, z = 28). The similarities and differences in brain activations
between TSPO HAB and MLAB are shown in Fig. 2.Table 4
Anatomical regions where brain activity is greater for TSPO MLAB than HAB during painfu
Anatomical region Cluster size x
L. superior temporal gyrus 445 42
R. primary sensory cortex 48 44
R. primary sensory cortex 34 18
R. secondary sensory cortex/temporal 27 68
R. dACC 127 10
R. primary sensory cortex 32 58
R. dACC 95 14
L. suppl. motor area 22 14
R. insula 57 38
R. insula 65 40
R. dlPFC 56 40
L. precentral gyrus 25 48
L. insula 21 42
Results are exploratory as they are reported at a liberal statistical threshold setting of p <
anatomical space as defined by the MNI standard brain atlas (Mazziotta et al., 1995).
anterior cingulate cortex, dlPFC = dorsolateral prefrontal cortex, TSPO = Translocator pro
Fig. 2. Similarities and differences in brain activations between TSPO MLAB and HAB. Co
MLAB (red) and HAB (cyan) patients. Regions with overlapping activity are grey. Anterior
are thresholded at a statistical level of p < 0.005, uncorrected for multiple comparisons, w
legend, the reader is referred to the web version of this article.)3.2.3. Psychophysiological interaction (PPI) Connectivity
3.2.3.1. Dorsolateral prefrontal cortex (dlPFC). A PPI-analysis of
pain-evoked functional connectivity revealed significant positive
connectivity between the right dlPFC and the right parietal cortex
(MNI peak coordinate: x = 50, y = 46, z = 58) in TSPO HAB patients
(n = 11), compared to MLAB (n = 13). In addition, TSPO HAB hadl stimulation (painful pressure - non-painful pressure).
y z Peak T-value P-value peak voxel
22 6 4.59 p < 0.001
38 66 4.34 p < 0.001
32 80 4.32 p < 0.001
38 18 4.17 p < 0.001
12 52 3.77 p < 0.001
22 52 3.71 p < 0.001
4 40 3.44 p < 0.001
8 76 3.41 p < 0.001
26 18 3.34 p < 0.001
14 2 3.34 p < 0.001
44 28 3.31 p < 0.001
4 20 3.15 p < 0.005
6 4 3.14 p < 0.005
0.005, uncorrected for multiple comparisons. Coordinates (x, y, z) correspond to the
Laterality (Left/Right) for anatomical regions are indicated with L/R. dACC = dorsal
tein, HAB = high affinity binders, MLAB = mixed/low affinity binders.
lors represent brain activity during painful pressure minus non-painful pressure in
and posterior orientation is denoted A/P. Left and Right is indicated with L/R. Results
ith 20 contiguous voxels. (For interpretation of the references to color in this figure
224 E. Kosek et al. / Brain, Behavior, and Immunity 58 (2016) 218–227significantly higher dlPFC connectivity within the right prefrontal
area (MNI peak coordinate: x = 38, y = 22, z = 26), compared to
TSPO MLAB. There were no regions where TSPO MLAB had higher
dlPFC connectivity compared to HAB (See Fig. 3).
3.2.3.2. Periaqueductal grey (PAG). As the PAG is a key brain region
for pain inhibition, a PPI analysis from a seed in the PAG was per-
formed. There was no significant difference in PAG brain connec-
tivity between the two TSPO genotype groups HAB/MLAB.4. Discussion
Female FM patients with genetically inferred TSPO HAB
reported more severe pain and more disability, compared to MLAB.
In addition, we found a strong interaction between the TSPO and 5-
HTT polymorphisms regarding pain severity. While the combina-
tion of genetically inferred TSPO HAB and high or intermediate
5-HTT expression was associated with higher pain intensities, the
opposite was true for 5-HTT low expressing individuals. To our
knowledge, this is the first evidence of a genetic functional poly-
morphism affecting pain severity in FM patients. Furthermore,
cerebral activation patterns during evoked pressure pain differed
between TSPO HAB and MLAB patients. A functional connectivity
analysis revealed that TSPO HAB was associated with higher pain
related functional connectivity, between the dlPFC and the parietal
cortex. These structures constitute the frontoparietal network and
are likely to be of major importance for vigilance as well as the
anticipation and appraisal of pain (Kong et al., 2013; Wager and
Atlas, 2015). In sum, we combine genetics and fuctional imaging
to suggest that TSPO-related mechanisms affect FM severity, possi-
bly by influencing the anticipatory and affective-motivational
components of cerebral pain processing.
4.1. The influence of the TSPO functional polymorphism on FM
symptoms
TSPO is widely expressed throughout the body and plays an
important role in integrating hormon- and redox-sensivite path-
ways. It exerts regulatory effects on processes such as steroidoge-
nesis, hormone synthesis, modulation of immune/inflammatory
processes and energy metabolism, particularly during oxidative
stress (Gatliff and Campanella, 2016). Our finding that FM symp-
tom severity was associated with the functional polymorphism of
TSPO (rs6971) can therefore hypothetically be explained by periph-
eral as well as central mechanisms. As peripheral abberations such
as mitochondrial dysfunction with oxidative stress and low grade
inflammation have been reported in FM patients (Cordero et al.,
2010, 2013; Sánchez-Domínguez et al., 2015) peripheral TSPO
effects could be of relevance. However, our finding that the TSPO
polymorphism was associated with differences in cerebral pain
related functional connectivity would suggest the involvement
also of central mechanisms, such as glia cell activation. The latter
is consistent with the report of elevated CSF concentrations of IL-
8 in FM patients (Kadetoff et al., 2012, Kosek et al., 2015), a chemo-
kine which is co-expressed with TSPO in glia cells and regulated by
TSPO (Liu et al., 2016).
Previous studies have documented increased glia expression of
TSPO in animal models of inflammatory (Hernstadt et al., 2009)
and neuropathic (Liu et al., 2016; Wei et al., 2013) pain. In these
pain models, TSPO agonists have analgesic and anti-hyperalgesic
effects, mediated by steroid/neurosteroid synthesis (Liu et al.,
2016). Similar results were found in a human positron emission
tomography study where the comparison between ten patient-
control pairs indicated an inverse correlation between TSPO bind-
ing in the thalamus and pain severity in chronic low back painpatients (Loggia et al., 2015). Therefore, our result showing more
severe pain and higher impact of FM symptoms in TSPO HAB than
MLABmay at first seem contra-intuitive. Yet, it is important to note
that TSPO effects may vary considerably with neurochemical con-
text and with time. Thus, there is evidence that the duration of the
painful condition affects the physiological effects of TSPO agonists
(Liu et al., 2016). Whereas TSPO may have analgesic effects and
promote recovery in the earlier stages when pain is still localized,
this may not apply once chronic widespread pain has developed.
Furthermore, given that the pain modulatory effects of TSPO are
mediated by neurosteroids synthesis (Liu et al., 2016), the net
effect will depend on the ratios of positive and negative GABA-A
receptor modulators, respectively. FM patients have elevated CSF
concentrations of substance P (Russell et al., 1994; Vaeroy et al.,
1988), which dose-dependently inhibit the synthesis of analgesic
neurosteroids (Patte-Mensah et al., 2014). Finally, serotonergic
tone influences neurosteroid synthesis, with low tone favouring
negative modulators (Pinna et al., 2006; Schüle et al., 2011) and
FM patients have lower CSF concentrations of serotonin metabo-
lites (Legangneux et al., 2001; Russell et al., 1992). The importance
of the serotonergic mechanisms for TSPO effects are further sup-
ported by the significant interaction between the TSPO and 5-
HTTLPR polymorphisms regarding pain severity in FM.4.2. The role of the 5-HTTLPR functional polymorphism in FM
The role of genetics has been extensively studied in FM (Ablin
and Buskila, 2015). In a genome-wide association study (GWAS)
the chromosomal region of 5-HTT was linked to FM in one study
(Arnold et al., 2013), but not confirmed in a subsequent study
(Docampo et al., 2014). It is important to note that the LPR as such,
is a DNA repeat that varies in length to produce a polymorphism.
This type of variation is not detected per se in GWAS studies, such
that one would have to rely on SNPs in high linkage disequilibrium
to detect a signal, a fact that may reduce statistical power. The 5-
HTTLPR (rs25531) has been reported in higher frequencies in FM
patients compared to controls (Offenbaecher et al., 1999; Cohen
et al., 2002), and was associated with psychological distress
(Offenbaecher et al., 1999). However, in the present study, no
effects of the triallelic 5-HTTLPR polymorphism on FM symptoms
were found when studied in isolation.4.3. Interactions between the TSPO and the 5-HTTLPR polymorphisms
We found a statistically significant interaction effect between
the TSPO and 5-HTTLPR polymorphisms regarding pain severity
in FM. In the TSPO MLAB group, higher pain severity was reported
by FM patients with the low expressing 5-HTT genotype, compared
to intermediate and high expressing, respectively. Paradoxically, in
the TSPO HAB group, the 5-HTT low expressing genotype was asso-
ciated with lower pain severity. The reduced serotonin transport
seen in the 5-HTT low expressing genotype has been reported to
be comparable to inhibition of 5-HTT during treatment with selec-
tive serotonin re-uptake inhibitors (SSRIs) (Serretti et al., 2007).
Since SSRIs promote the synthesis of neurosteroids with analgesic
effects (Kawano et al., 2011; Pinna et al., 2006; Serretti et al., 2007),
this mechanism could hypothetically explain why SSRIs can have
beneficial effects on FM symptoms (Carville et al., 2008; Haüser
et al., 2012). If, also the 5-HTT low expressing genotype favours
the synthesis of neurosteroids with analgesic effects, then this
would explain the reduced pain in TSPO HAB FM patients com-
pared to MLAB seen in our study, since the impact would be more
pronounced in TSPO HAB with an expected higher rate of neuros-
teroid synthesis.
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To our knowledge this is the first report linking a functional
genetic polymorphism to pain and symptom severity and demon-
strating gene-to-gene interactions on symptom severity in FM. The
finding that FM symptoms are associated with genetic variations of
TSPO (rs6971) is consistent with the hypothesis of glia activation
(Clauw, 2015; Kadetoff et al., 2012) and suggests that the ongoing
drug development targeting TSPO associated neurosteroid mecha-
nisms (Pinna et al., 2006) could be beneficial for treating FM. In
addition, the significant interactions between TSPO and 5-HTT
polymorphisms stress the importance to assess gene-to-gene
interactions, which will hopefully result in more consistent, repro-
ducible results. Furthermore, the results suggest that genotyping
could become a valuable tool for patient stratification in treatment
studies and form part of individualized medicine in clinical prac-
tice. For example, despite the fact that antidepressants play a
major role in the treatment of pain in FM (Haüser et al., 2012),
the analgesic response is typically very heterogenous (Jensen
et al., 2014). Based on our results the most likely responders to
SSRI/SNRI treatment regarding pain relief would be found among
FM patients with the TSPO HAB genotype. The latter was supported
by the lack of statictically significant difference in SF-36 BP
between TSPO HAB and MLAB among patients taking antidepres-
sants, as opposed to those who were not. This hypothesis should
be tested in a large clinical trial.
4.5. Neuroimaging results related to the TSPO polymorphism
In line with the effects of the TSPO polymorphism on pain
reports, there was a segregation of functional brain connectivity
depending on TSPO genotype, when comparing differences in cere-
bral responses to pressure pain. Using a liberal statistical threshold
(i.e. uncorrected for multiple comparisons), there were indications
that MLAB patients displayed higher activation in nociceptive and
pain modulatory areas, compared to HAB patients, including
somatosensory cortices, dACC and dlPFC. Our univariate data indi-
cate that the TSPO polymorphisms may influence cerebral process-
ing of pain in FM patients, but need to be replicated in a larger
cohort before more definite conclusions can be drawn.
Psychophysiological interaction (PPI), including anatomical
seed coordinates in the dlPFC and PAG, was used to examine if
these regions displayed differences in functional connectivity
depending on TSPO genotype. We found significantly increased
pain-related connectivity in the frontoparietal network in TSPO
HAB individuals, compared to MLAB, using the dlPFC as seed
region. The frontoparietal network includes the dlPFC and parietal
cortex and has been implicated in expectancy-induced modulation
of pain (Kong et al., 2013; Wager and Atlas, 2015). More specifi-
cally, it has been suggested that the frontoparietal network inte-
grates information from the external environment with stored
internal representations, and controls top-down attention during
conflicting sensory processing (Kong et al., 2013).
Interestingly, the frontoparietal network (Wager et al., 2011) as
well as dlPFC (Wager et al., 2004) have been implicated in placebo
analgesia, supporting their role in endogenous pain regulation.
However, the analgesic placebo effects involving activation of
dlPFC were also reflected as increased connectivity between these
structures and PAG (Wager and Atlas, 2015). The fact that PAG did
not display any differences in pain-evoked connectivity between
groups is in line with the lack of difference in pressure pain sensi-
tivity between the TSPO HAB and MLAB groups. Thus, our results
do not support the notion that the TSPO polymorphism modulates
top-down regulation of nociceptive input, i.e., the more sensory-
discriminative aspects of nociception. Rather, our findings suggest
that TSPO may affect cognitive and affective-motivational aspectsof pain, as TSPO HAB patients reported larger negative impact of
pain, and more intense clinical symptoms.
4.6. Limitations
The study has several limitations. First, we assessed the genet-
ically inferred binding affinity to TSPO as well as the genetically
inferred expression of 5-HTT only. Also due to the limited number
of patients examined by fMRI, the gene-to-gene interactions
regarding cerebral pain processing could not be assessed. The data
presented are baseline data from subjects enrolled in a clinical trial
assessing the effects of exercise on FM symptoms, therefore we can
not exclude a certain bias towards less disabled subjects, compared
to FM patients typically seen at specialized pain clinics.
4.7. Conclusions
Female FM patients with genetically inferred TSPO HAB
reported higher pain severity and more severe FM symptoms com-
pared to MLAB. To our knowledge this is the first report of a func-
tional genetic polymorphism affecting pain severity in FM. There
was further a strong gene-to-gene interaction between the TSPO
and the 5-HTTLPR polymorphisms, indicating the modulatory
importance of serotonergic mechanisms. Finally, the TSPO poly-
morphismwas associated with different pain related cerebral func-
tional connectivity patterns, suggesting an effect of TSPO related
mechanisms on the affective-motivational components of pain
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